[1]郭彦茹,刘珂欣,孙子月,等.活血化浊饮治疗芳香化酶抑制剂相关乳腺癌术后血脂异常的生信机制研究[J].西部中医药,2026,39(08):89-97.[doi:10.12174/j.issn.2096-9600.2026.08.17]
　GUO Yanru,LIU Kexin,SUN Ziyue,et al.A Bioinformatics-Based Mechanistic Study of Blood-Activating and Turbidity-Resolving Decoction in the Treatment of Aromatase Inhibitor-associated Dyslipidemia in Postoperative Breast Cancer Patients[J].Western Journal of Traditional Chinese Medicine,2026,39(08):89-97.[doi:10.12174/j.issn.2096-9600.2026.08.17]
点击复制

活血化浊饮治疗芳香化酶抑制剂相关乳腺癌术后血脂异常的生信机制研究()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
39
期数:
2026年08期
页码:
89-97
栏目:
二次研究
出版日期:
2026-07-29

文章信息/Info

Title:
A Bioinformatics-Based Mechanistic Study of Blood-Activating and Turbidity-Resolving Decoction in the Treatment of Aromatase Inhibitor-associated Dyslipidemia in Postoperative Breast Cancer Patients
作者:
郭彦茹, 刘珂欣, 孙子月, 叶媚娜
上海中医药大学附属龙华医院，上海 200030
Author(s):
GUO Yanru, LIU Kexin, SUN Ziyue, YE Meina
Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China
关键词:
乳腺癌; 活血化浊饮; 芳香化酶抑制剂; 血脂异常; 生物信息学分析
Keywords:
breast cancer; blood-activating and turbidity-resolving decoction; aromatase inhibitor; dyslipidemia; bioinformatics
分类号:
R285
DOI:
10.12174/j.issn.2096-9600.2026.08.17
文献标志码:
A
摘要:
目的基于GEO数据库联合生物信息学分析，研究活血化浊饮治疗芳香化酶抑制剂相关乳腺癌患者术后血脂异常的作用机制。 方法采用中药系统药理学数据库与分析平台（traditional Chinese medicine systems pharmacology database and analysis platform，TCMSP）检索获取活血化浊饮的已知化学成分及其靶点，在UniProt数据库中对所得靶点进行基因名标准化；采用Cytoscape软件构建药物-成分-靶点网络图。通过GEO数据库及GeneCards数据库收集芳香化酶抑制剂干预乳腺癌患者的疾病靶点，并与血脂异常相关靶点取交集；采用DAVID数据平台进行基因本体论（gene ontology，GO）功能富集分析和京都基因与基因组百科全书（Kyoto encyclopedia of genes and genomes，KEGG）通路分析。 结果从活血化浊饮中筛选出药代动力学特性较好的活性成分95种，包括槲皮素、谷甾醇、大黄酸、决明子素、丹参酮、丹参酚等。基于主要活性成分及芳香化酶抑制剂干预原发性乳腺癌相关血脂异常的差异基因分析显示，上调基因298个、下调基因8个。GO功能富集分析（P＜0.05）筛选出10个条目，其中生物过程包括基因表达的正调控、脂蛋白分解代谢过程、胆固醇流出、受体介导的内吞作用、胞内运输等，均与脂质代谢密切相关。通过KEGG通路分析筛选得到10条信号通路，包括脂质和动脉粥样硬化通路、雌激素信号通路、流体剪切应力与动脉粥样硬化的相互作用通路等；其中与血脂异常代谢及其功能相关的关键靶点为NCOA1、MMP9、CTSD，推测其可能是活血化浊饮治疗绝经后乳腺癌血脂异常的关键靶点，并完成相关分子对接验证。 结论研究初步揭示，活血化浊饮可通过多成分、多靶点、多通路调节芳香化酶抑制剂相关乳腺癌患者的血脂异常，主要从抗炎、抗氧化等方面发挥作用，为进一步研究活血化浊饮治疗绝经后乳腺癌血脂异常提供了科学依据。
Abstract:
ObjectiveTo investigate the mechanism of blood-activating and turbidity-resolving (Huoxue Huazhuo) decoction in the treatment of aromatase inhibitor-associated dyslipidemia in postoperative breast cancer patients using the GEO database and bioinformatics analysis. MethodsThe known chemical components and their targets of blood-activating and turbidity-resolving decoction were retrieved using the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP). Gene names of the obtained targets were standardized in the UniProt database. A drug-component-target network was constructed using Cytoscape software. Disease targets related to aromatase inhibitor intervention in breast cancer patients were collected from the GEO database and GeneCards database, and then intersected with dyslipidemia-related targets. Gene Ontology (GO) functional enrichment analysis and Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis were performed using the DAVID data platform. ResultsA total of 95 active components with favorable pharmacokinetic properties were screened from blood-activating and turbidity-resolving decoction, including quercetin, sitosterol, rhein, obtusifolin, tanshinone, salvianolic acid, and others. Differential gene analysis based on the main active components and aromatase inhibitor intervention in primary breast cancer-associated dyslipidemia revealed 298 upregulated genes and 8 downregulated genes. GO functional enrichment analysis (P<0.05) identified 10 terms. Among them, the biological processes included positive regulation of gene expression, lipoprotein catabolic process, cholesterol efflux, receptor-mediated endocytosis, and intracellular transport, all of which were closely related to lipid metabolism. KEGG pathway analysis screened out 10 signaling pathways, including the lipid and atherosclerosis pathway, estrogen signaling pathway, and fluid shear stress and atherosclerosis pathway. NCOA1, MMP9, and CTSD were identified as key targets associated with dyslipidemia metabolism and its function. These are speculated to be the key targets of the decoction in the treatment of postmenopausal breast cancer-associated dyslipidemia, and relevant molecular docking validation was completed. ConclusionThis study preliminarily reveals that the decoction can regulate aromatase inhibitor-associated dyslipidemia in breast cancer patients through multiple components, multiple targets, and multiple pathways, primarily exerting its effects through anti-inflammatory and antioxidant mechanisms. These findings provide a scientific basis for further research on blood-activating and turbidity-resolving decoction in the treatment of postmenopausal breast cancer-associated dyslipidemia.

相似文献/References:

[1]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101.
　WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(08):101.
[2]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[3]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[4]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[5]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[6]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[7]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[8]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(08):1.
[9]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
　AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(08):7.
[10]朱竹华,许敏菊,张汀荣,等.以家庭为中心的护理模式在完全植入式静脉输液港乳腺癌化疗患者中的应用[J].西部中医药,2016,29(03):114.
　ZHU Zhuhua,XU Minju,ZHANG Dingrong,et al.FCC Applying to Breast Cancer Patients Who Received Chemotherapy by TIVAP[J].Western Journal of Traditional Chinese Medicine,2016,29(08):114.

备注/Memo

备注/Memo:
国家自然科学基金面上项目（82374252）。郭彦茹（1997—），女，硕士学位，医师。研究方向：乳腺良恶性疾病的中医诊治及研究。Email：G41598R@163.com。
更新日期/Last Update: 2026-08-15